Skip to content

China Biologic Products Holdings, Inc.

Delisted

CIK 1369868fmd_02MX15N5ZHECBMJ1CFEANNGN49Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2009 to Dec 31, 2019, 33 periods

Latest annual · FY2019

Millions
Total revenues
504
Gross profit
329
Operating income
164
Net income
139
Free cash flow
205

Latest quarter · Q2 FY2017

Millions
Total revenues
89
Gross profit
59
Operating income
39
Net income
31
Free cash flow
17
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2016 to FY2019
+13.9%
Revenue, 5 yearsFY2014 to FY2019
+15.7%
Net income, 5 yearsFY2014 to FY2019
+14.4%

China Biologic Products Holdings, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2019FY2018ChangeSource
Revenue$503.7 million$466.9 million+7.9%20-F 2020-03-12 · proof
Gross profit$329.1 million$320.1 million+2.8%20-F 2020-03-12 · proof
Operating income$163.6 million$146.2 million+12%20-F 2020-03-12 · proof
Net income$138.8 million$128.1 million+8.4%20-F 2020-03-12 · proof
Cash from operating activities$229.3 million$103.9 million+120.6%20-F 2020-03-12 · proof
Free cash flow$205.1 million$72.2 million+184%20-F 2020-03-12 · proof
Total assets$1.9 billion$2 billion-3.6%20-F 2020-03-12 · proof
Total liabilities$163 million$165.3 million-1.4%20-F 2020-03-12 · proof
Cash and cash equivalents$161.8 million$338.9 million-52.3%20-F 2020-03-12 · proof
What was China Biologic Products Holdings, Inc.'s revenue in fiscal 2019?
China Biologic Products Holdings, Inc. reported revenue of $503.7 million for fiscal 2019 (the year ended Dec 31, 2019), against $466.9 million the year before (+7.9%). Source: the 20-F filed with the SEC on Mar 12, 2020. SEC
What was China Biologic Products Holdings, Inc.'s gross profit in fiscal 2019?
China Biologic Products Holdings, Inc. reported gross profit of $329.1 million for fiscal 2019 (the year ended Dec 31, 2019), against $320.1 million the year before (+2.8%). Source: the 20-F filed with the SEC on Mar 12, 2020. SEC
What was China Biologic Products Holdings, Inc.'s operating income in fiscal 2019?
China Biologic Products Holdings, Inc. reported operating income of $163.6 million for fiscal 2019 (the year ended Dec 31, 2019), against $146.2 million the year before (+12%). Source: the 20-F filed with the SEC on Mar 12, 2020. SEC
What was China Biologic Products Holdings, Inc.'s net income in fiscal 2019?
China Biologic Products Holdings, Inc. reported net income of $138.8 million for fiscal 2019 (the year ended Dec 31, 2019), against $128.1 million the year before (+8.4%). Source: the 20-F filed with the SEC on Mar 12, 2020. SEC
What was China Biologic Products Holdings, Inc.'s cash from operating activities in fiscal 2019?
China Biologic Products Holdings, Inc. reported cash from operating activities of $229.3 million for fiscal 2019 (the year ended Dec 31, 2019), against $103.9 million the year before (+120.6%). Source: the 20-F filed with the SEC on Mar 12, 2020. SEC
What was China Biologic Products Holdings, Inc.'s free cash flow in fiscal 2019?
China Biologic Products Holdings, Inc. reported free cash flow of $205.1 million for fiscal 2019 (the year ended Dec 31, 2019), against $72.2 million the year before (+184%). Source: the 20-F filed with the SEC on Mar 12, 2020. SEC
What are China Biologic Products Holdings, Inc.'s total assets?
As of Dec 31, 2019, China Biologic Products Holdings, Inc. reported total assets of $1.9 billion, against $2 billion a year earlier (-3.6%). Source: the 20-F filed with the SEC on Mar 12, 2020. SEC
What are China Biologic Products Holdings, Inc.'s total liabilities?
As of Dec 31, 2019, China Biologic Products Holdings, Inc. reported total liabilities of $163 million, against $165.3 million a year earlier (-1.4%). Source: the 20-F filed with the SEC on Mar 12, 2020. SEC
What are China Biologic Products Holdings, Inc.'s cash and cash equivalents?
As of Dec 31, 2019, China Biologic Products Holdings, Inc. reported cash and cash equivalents of $161.8 million, against $338.9 million a year earlier (-52.3%). Source: the 20-F filed with the SEC on Mar 12, 2020. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1369868&period_type=annual&limit=5"

Information only, not investment advice.